Cocrystal Pharma Terminates Material Agreement
Ticker: COCP · Form: 8-K · Filed: Mar 1, 2024 · CIK: 1412486
| Field | Detail |
|---|---|
| Company | Cocrystal Pharma, INC. (COCP) |
| Form Type | 8-K |
| Filed Date | Mar 1, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, 8-k
TL;DR
Cocrystal Pharma terminated a key deal, filing an 8-K on March 1st.
AI Summary
Cocrystal Pharma, Inc. announced on February 28, 2024, the termination of a material definitive agreement. The company, incorporated in Delaware, filed this 8-K report on March 1, 2024, detailing this event. The filing also includes financial statements and exhibits.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, partnerships, and financial outlook.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement introduces uncertainty regarding the company's strategic direction and financial performance.
Key Players & Entities
- Cocrystal Pharma, Inc. (company) — Registrant
- February 28, 2024 (date) — Date of earliest event reported
- March 1, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
FAQ
What was the specific material definitive agreement that was terminated?
The filing states the termination of a material definitive agreement but does not specify which agreement was terminated.
When was the agreement terminated?
The earliest event reported, which includes the termination, was on February 28, 2024.
What are the implications of this termination for Cocrystal Pharma?
The filing does not detail the specific implications, but the termination of a material agreement typically affects operations, partnerships, and financial performance.
Are there any financial statements included with this filing?
Yes, the filing indicates that financial statements and exhibits are included.
What is the company's principal executive office address?
The principal executive offices are located at 19805 N. Creek Parkway, Bothell, WA 98011.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-03-01 16:15:38
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-24-008493.txt ( ) — 205KB
- cocp-20240228.xsd (EX-101.SCH) — 3KB
- cocp-20240228_lab.xml (EX-101.LAB) — 33KB
- cocp-20240228_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 1, 2024 Cocrystal Pharma, Inc. By: /s/ James Martin Name: James Martin Title: Chief Financial Officer and Co-Chief Executive Officer